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Introduction
Cardiovascular diseases are a major cause of morbidity and mortality,
accounting for 45% of all deaths in European countries in 20161 and
almost a third of deaths worldwide in 2013.2 A similar pattern is
observed in the UK where cardiovascular diseases were responsible
for 27% of deaths in 2014, with coronary heart disease resulting in
the largest number of deaths attributable to a single cause
(n =69 000) whilst stroke is the third biggest cause (n =39 000).3
Although age-standardized cardiovascular disease mortality rates are
decreasing worldwide, the total deaths and burden as measured
through disability-adjusted life years of cardiovascular diseases are
increasing.4,5 Furthermore, in the UK, cardiovascular risk factors such
as high blood pressure and high cholesterol are among the leading
causes of disease burden.6
Epidemiological studies have historically played an essential role in
identifying the causes and consequences of cardiovascular disease
and have resulted in improvements in prevention and treatment. The
seminal US-based Framingham Heart Study which recruited 5200
participants between 1948 and 1952, was integral in identifying a
range of important risk factors for cardiovascular disease, such as
high blood pressure, a high cholesterol level, cigarette smoking, obes-
ity and physical inactivity, and consequently shifted the focus from
management to preventative strategies for cardiovascular disease.7
This, together with findings from other epidemiological studies, such
as the Seven Countries Study and the MONICA project,8 have been
influential in leading to treatments for the primary and secondary pre-
vention of cardiovascular events, most notably statins (that act to
lower cholesterol levels), and anithypertensives.9,10
Epidemiological studies such as the Framingham Heart Study with
moderate sample sizes are useful in detecting risk factors with large
effects on common outcomes; however, they lack statistical power
to reliably identify risk factors which have small to moderate effects
or to assess associations with disease across subgroups of the popu-
lation. The need for large sample sizes has led to collaborative efforts,
such as the Prospective Studies Collaboration (an individual
participant meta-analysis of data from 61 studies and more than a mil-
lion participants11) that has demonstrated conclusively that a con-
tinuous increase in blood pressure corresponds with an increased
risk of vascular death across all age groups (see Figure 1 that illustrates
the importance of a large sample size (about 500 000 participants) for
detecting this association).12 Sample size is also of particular import-
ance in the current era of genome-wide association studies, where
many investigations are aiming to detect either small effects from
common variants or large effects from rare variants.13
The causes of cardiovascular disease involve a complex interplay be-
tween predisposing genetic factors and lifestyle, environmental, and
health-related exposures. Furthermore, cardiovascular risk factors are
likely involved in the development of non-cardiovascular diseases, such
as Alzheimer’s disease.14 Large prospective studies that collect an ex-
tensive range of exposures before the subsequent development of dis-
ease are essential in order to gain novel insights into the causes and
consequences of cardiovascular (and non-cardiovascular) diseases.
Although there are many cohort studies with large sample sizes and
biological samples, they generally consist of less comprehensive data
collection (see Table 1 for overview of major studies). In order to ad-
dress this, UK Biobank was established as a prospective cohort study
that combines a large sample size with a very wide range of data on ex-
posures and outcomes in order to improve the prevention, diagnosis
and treatment of diseases of middle and old age, including cardiovascu-
lar diseases such as heart disease and stroke.15–17
UK Biobank
Between 2006 and 2010, half a million participants aged 40–69 years
who lived within 25 miles of one of the 22 assessment centres
located throughout England, Wales and Scotland were recruited into
UK Biobank. At the assessment centres, participants provided elec-
tronic signed consent, answered touchscreen and verbal interview
questions on sociodemographic, lifestyle, environmental, and health-
related factors, completed a range of physical measures and provided
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.blood, urine, and saliva samples (see Table 2 for further detail on
measures collected at baseline). Once recruitment was fully under-
way, further enhancements were introduced to the assessment visit,
with large subsets of the cohort undergoing a range of eye measures,
heel bone ultrasound, an electrocardiograph test, pulse wave vel-
ocity, and a hearing test. A large amount of the data collected at base-
line has direct relevance to cardiovascular disease and health,
including, but not limited to, self-reported information on medica-
tions and health conditions, family history of cardiovascular disease,
measures of arterial stiffness, blood pressure, cardiorespiratory fit-
ness, body size, and body fat.
The cohort is not representative of the general population (e.g.
participants are more likely to live in less socio-economically
deprived areas and have lower death rates than the general popula-
tion), so is unsuitable for estimating disease prevalence and incidence
rates. However, it is well-designed to reliably detect generalizable as-
sociations between most baseline characteristics and health out-
comes due to the sufficiently large numbers of participants across the
full distribution of exposures. For example, whilst the number of cur-
rent smokers is low in UK Biobank compared with the general popu-
lation, there are sufficiently large numbers of smokers to detect the
association with various diseases.
Enhancements to data collection
The UK Biobank resource is continuously being enhanced through
additional phenotyping (see Table 3 for further detail on ongoing data
collection). The samples from all 500 000 participants are currently
being assayed for a range of selected biomarkers, many of which have
been implicated in the development of cardiovascular disease (e.g.
cholesterol, direct low-density lipoprotein, high-density lipoprotein,
lipoprotein (a), triglyceride, apolipoprotein A, apolipoprotein B, and
C-reactive protein).
Genotyping of 820 000 single nucleotide polymorphisms and
insertion-deletion markers has been performed using a bespoke
genome-wide array, designed collaboratively by a group of leading
academics and Affymetrix, with centralized quality control and imput-
ation to >70 million variants. The genotyping array includes thou-
sands of markers that are involved in cardiometabolic processes and
blood pressure regulation, rare variants associated with cardiac dis-
ease and those involved in the absorption, distribution, metabolism,
and excretion of drugs (Figure 2).18 This data will enable researchers
to explore the genetic determinants of cardiovascular disease, con-
duct Mendelian randomization experiments to identify potentially
causal effects and investigate gene-environment interactions.
Subsets of the cohort are invited to have a repeat assessment
every few years (the first of which was performed during 2012–13 on
20 000 participants) to allow for correction for regression dilution
bias caused by measurement error or intra-individual changes in ex-
posures and biomarkers.19
UK Biobank is undertaking multimodal imaging in 100 000 partici-
pants.20 Imaging measures relevant for cardiovascular research
include cardiac magnetic resonance imaging (MRI), which measures
the left and right ventricles and atrium, aorta and aortic valve
Figure 1 Absolute risk of ischaemic heart disease mortality by usual systolic blood pressure and age at risk in 5000, 50 000, and 500 000 partici-
pants. Unpublished figure containing data from the Prospective Studies Collaboration, obtained through personal communication. CI, confidence
interval; IHD, ischaemic heart disease.
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(see Figure 3 e.g. of cardiac MRI images performed in UK Biobank),21
an ultrasound of the carotid arteries22 and a resting 12-lead electro-
cardiogram (ECG).23 The other imaging modalities include an MRI of
the brain and body and a whole body dual-energy X-ray absorpti-
ometry (DXA) of the bones and joints. These modalities also capture
information of relevance to cardiovascular health, e.g. white matter
lesions on T2-weighted brain MRI scans as well as fat distribution
from liver and pancreatic MRI scans.
Analytical pipelines are being set up so that derived phenotypes,
such as detailed measures of brain structure and function, body fat
distribution and cardiac function can be made available for re-
searchers. The imaging assessment began in 2014 with a pilot study of
6000 participants and is now being expanded to three assessment
centres over the next few years. Imaging data will be released in
tranches every 6–12 months as it becomes available so researchers
can continuously refresh their analyses throughout the course of
their project without having to wait until the end of the imaging study
(2020 or later).
Data are also being collected from web-based questionnaires that
focus on the collection of more detailed information on exposure
(such as dietary habits and occupational history) and of outcomes
that are difficult to ascertain through electronic health records (such
as cognitive function, mental health, irritable bowel syndrome, pain,
and quality of life).
Capturing health outcomes through data
linkage
A major advantage of UK Biobank is that all participants at recruit-
ment were registered with a general practitioner in the National
Health Service (NHS) and consented to linkage to their health-
related records. The NHS provides nationwide healthcare in the UK
and keeps detailed records of health-related information. As a result,
UK Biobank can follow-up all participants’ health outcomes through
linkage to a range of national datasets. Currently, data from national
death and cancer registries and hospital inpatient records are avail-
able whilst efforts are underway to integrate data from primary care,
screening programmes, and disease-specific registries (See Table 4 for
more detail on health-records).
Linking to a wide range of health record datasets will provide a rich
amount of data. However, it also introduces the daunting challenge of
harmonizing information across multiple sources to produce reliable
and valid outcomes. In order to ensure effective use of the resource,
UK Biobank aims to develop scalable approaches not only for the as-
certainment of the many thousands of many different health-related
outcomes that will occur during prolonged follow-up (as well as those
that occurred prior to recruitment) but also for their sub-classification
and detailed characterization. This will be achieved through a staged
approach of initially ascertaining cases using linked data, then increasing
the accuracy of diagnoses by cross-referencing multiple sources of in-
formation, starting with the ascertainment of health outcomes using
lower-cost linked health-related data sources,24,25 and proceeding to
more intensive methods (e.g. retrieval of imaging or laboratory data)
for validation and sub-classification.
Expert-led health outcome subgroups are guiding the develop-
ment and testing of approaches for a wide range of conditions









































































































































































































































































































































































































































































































































































































































































































.neurodegenerative, and mental health disorders, renal and eye dis-
eases). These adjudicated outcomes will provide an invaluable re-
source for researchers interested in investigating cardiovascular
disease, or non-cardiovascular diseases in the context of cardiovascu-
lar research, but who do not have the time or expertize to derive
these outcomes themselves. Alternatively, researchers who are
interested in developing their own algorithms to enhance the classifi-
cation of diseases or extract useful information from the medical re-
cords have access to an increasing diversity of linked data.
UK Biobank and implications for
cardiovascular health and disease
research
Observational studies tend to focus on either collecting a diverse
range of measures from a small number of participants or less de-
tailed information on a large number of participants. In contrast, UK
Biobank combines a large sample size with extensive phenotypic and
genotypic data as well as ongoing follow-up of participant’s health
through linkage to electronic medical records. The obvious advan-
tage of conducting research on a single large well-phenotyped
population is that the assays and measurements have been per-
formed in a standardized way as opposed to integrating data from
multiple studies consisting of widely varying participant characteris-
tics and different methodologies.
The unprecedented depth and breadth of data available in UK
Biobank offers unparalleled opportunity to address a wide range of
research questions related to cardiovascular health outcomes.
Classification and sub-classification of diseases can be enhanced
through combining the diverse phenotypic and genotypic data with
medical records. The large sample size enables researchers to per-
form risk stratification on well-defined phenotypes to focus on high-
and low-risk populations for cardiovascular disease, e.g. those with
the lowest and highest levels of circulating lipid levels. Additionally,
mechanistic pathways between risk factors and outcomes can be
explored using the genetic, biomarker and imaging data. UK Biobank
is already the largest-ever multimodal imaging study; previous studies
that have incorporated cardiovascular imaging have usually included a
few thousand participants, which has limited the potential research
opportunities available.20 UK Biobank will provide sufficient statistical
power to investigate imaging derived phenotypes in association with
a range of incident health outcomes, as well as the interplay between
the heart, body and brain in determining disease risk.
....................................................................................................................................................................................................................
Table 2 Overview of data collected at baseline assessment in 2006–10
Topics/measures Details
Touchscreen questionnaire and computer assisted verbal interview
Sociodemographics Ethnicity, education, employment, household information, Townsend deprivation index (social class)
Lifestyle and environment Smoking, alcohol consumption, physical activity, diet, sleep, electronic device use, sun exposure, and sexual factors
Early life factors Birthplace, birth weight, breastfed, childhood body size and height, maternal smoking, handedness, adopted, and
part of multiple birth
Family history Illnesses of father/mother/siblings, age of parents, age parents died, and number of siblings
Psychosocial factors Social support, bipolar/major depression, anxiety, nerves, psychological traits, and mood
Health and medical history Medical conditions, medications, operations, cancer screening, pain, oral health, eyesight, hearing, and general health
Sex-specific factors Male specific—first facial hair, age voice broke, hair/balding pattern, children fathered; female specific—hormone-
replacement therapy, contraception, pregnancy, menstruation, menopause, and cervical test
Cognitive function Prospective memorya, pairs matching, fluid intelligencea, reaction time, and numeric memoryb
Hearing testa Speech-in-noise
Physical measures
Blood pressure and pulse rate Two measures taken 1 min apart using a digital blood pressure monitor
Arterial stiffnessa Pulse wave velocity using infra-red sensor at the finger
Grip strength Right and left hand isometric grip strength
Anthropometrics Standing/sitting height, waist/hip circumference, weight body mass index, and whole body bio-impedance measures
Spirometry Two to three blows within a 6 min period
Bone mineral density Ultrasound measurement of the heel
Eye measuresc Eye surgery complications, visual acuity, autorefraction, intraocular pressure, and retinal coherence tomography
Fitness testc Heart rate monitoring using a four-lead electrocardiograph during cycle ergometry on a stationary bike
Sample collection
Blood 45 mL divided into 6 tubes, includes whole blood, serum, plasma, red cells, buffy coat
Urine 9 mL in 1 tube
Salivac 2.5 mL in 1 tube
aPerformed in last 200 000 participants.
bPerformed in 50 000 participants (as part of the pilot study).
cPerformed in last 100–150 000 participants.
UK Biobank 5
....................................................................................................................................................................................................................
Table 3 Overview of ongoing data collection and enhanced phenotyping
Data Details Date collected Date available for
research use
Genotyping Blood collected at baseline for the full cohort has been
genotyped by two arrays that share 95% common
content (the UK BiLEVE array for 50 000 participants
and the UK Biobank Axiom array for 450 000 partici-
pants). The array covers 800 000 SNPs and indel
markers covering markers of specific interest, rare
coding variants and genome-wide coverage. Seventy-
three million SNPs, short indels, and large structural
variants have been imputed using the UK10K haplo-
type reference panel merged with the 1000 Genomes





150 000 in Q4 2015;
350 000 in Q2 2017
Biochemical measures Thirty-four biomarkers are being assayed using the
plasma, serum, red blood cells, and urine samples.
Biomarkers were selected because they are estab-
lished risk factors for disease (e.g. sex hormones for
cancer), diagnostic measures (e.g. HbA1C for dia-
betes) or they are used to characterize phenotypes
(e.g. cystatin C and creatinine for renal function). For






Red blood cells and
serum biomarkers in
Q3–Q4 2017
Repeat of baseline assessment Twenty-thousand participants repeated all baseline as-
sessment measures at one assessment centre,
Stockport, UK. These will be repeated every few
years.
2012–13 Q3 2013
Web-based questionnaires Participants with email addresses (330 000) are sent
web-based questionnaires once or twice a year to
collect more detailed information on exposures or
health outcomes that are difficult to capture through
linkage to electronic health records.
24-h dietary recall Includes information on consumption of over 200 food
and drink items over the last 24 h and was used to
generate estimated daily nutrient intakes. The ques-
tionnaire was sent on four occasions over a 16-month
period to capture variation in diet. 176 012 partici-
pants completed the questionnaire at least once (53%
response rate) and 27 535 completed it four times
(16%).
2011–12 Q2 2013
Cognitive function Includes a series of cognitive tests, of which four were
repeated from the baseline assessment (fluid intelli-
gence, reaction time, numeric memory, pairs test) in
addition to two further tests (trail making, symbol
digit substitution). 120 000 participants completed
this questionnaire (36% response rate).
2014 2015
Occupational history Included information on lifetime employment history,
occupational exposures and related medical informa-
tion. 117 500 participants completed this question-
naire (35% response rate).
2015–16 2015
Mental health Included information on lifetime mental health events
(including depression, bipolar affective disorder, and
2016 Q2 2017
Continued












UK Biobank has also included a range of physical measures to com-
plement self-reported information which is prone to various biases,
e.g. the collection of objective physical activity on 100 000 partici-
pants using accelerometers, allowing the quantification of the type
and amount of physical activity in association with cardiovascular
health, as well as the relationship with other factors such as sedentary
behaviour, obesity, and body fat as measured through imaging.
The prospective nature of UK Biobank as well as the large sample
size has enabled a large number of incident events to be captured
through cohort-wide follow-up, including 40 000 incident cancers,
14 000 deaths and 1.3 million hospitalizations, a substantial number
of which are attributable to cardiovascular disease. By end of March
2015, there were 5800 incident cases of myocardial infarction and
3600 incident cases of stroke using an adjudicated algorithm that
Figure 2 Overview of the genetic markers measured on the UK Biobank Axiom Array. ADME, absorption, distribution, metabolism, and excre-
tion; ApoE, apolipoprotein E; CNV, copy number variants; eQTL, expression quantitative trait loci; GWAS, genome-wide association study; HLA,
human leucocyte antigen; k, thousand; KIR, killer cell immunoglobulin-like receptors; MAF, minor allele frequency; mtDNA, mitochondrial DNA;
NHGRI, National Human Genome Research Institute.
....................................................................................................................................................................................................................
Table 3 Continued
Data Details Date collected Date available for
research use
generalized anxiety disorder), alcohol and cannabis
use, unusual and psychotic experiences, traumatic
events, self-harm behaviours and subjective wellbeing.
137 400 participants completed this questionnaire
(45% response rate).
Accelerometry 100 000 participants wore an Axivity AX3 tri-axial wrist
accelerometer for a 7-day period. Derived summary
data on duration and intensity of activity available.
2013–15 2015
Multi-modal imaging MRI of brain, heart and body, carotid ultrasound and


























































..incorporates self-report, death and hospital inpatient data. When pri-
mary care data are made available for the full cohort, it is anticipated
that the number of cases will increase by 10–15% for myocardial in-
farction and 50% for stroke. This linkage will not only aid the ascer-
tainment of certain conditions underdiagnosed in a hospital inpatient
setting, but will also provide information on laboratory and physical
measurements, referrals, and prescriptions. The large number of
events allows the exploration of well-powered exposure-outcome
associations as well as the development and/or validation of risk pre-
diction models.26
Accessing UK Biobank data
UK Biobank is an open-access resource which any bona fide researcher
can apply to use (without the need for collaboration with UK Biobank
scientists), to conduct health-related research that is in the public
good. Applications to use the UK Biobank resource can be made from
researchers from the academic, commercial, charity, or public sector,
from either the UK or internationally, with access being granted on a
non-preferential and non-exclusive basis. Once researchers have regis-
tered with UK Biobank (www.ukbiobank.ac.uk), they can submit an ap-
plication, which involves a brief description of the scientific rationale,
aims, methodology and expected value of the project. Researchers se-
lect the required data-fields through the data showcase (www.ukbio
bank.ac.uk/data-showcase/), which provides complete information on
each variable available, how it was collected and the univariate distribu-
tion of participants across categories. Following approval by the Access
Sub-Committee, researchers are required to sign a Material Transfer
Agreement before downloading the data.
Applications can be for data only, sample requests or proposals to
re-contact participants. The main requirement for data only applica-
tions is that the scope of the application can be clearly defined.
Applications can be hypothesis-driven or hypothesis generating, in-
volve a range of phenotypic/genotypic data or be focused on de-
veloping novel methods. Applications that request biological samples
are subject to higher levels of scrutiny due to the depletable nature
of the resource; researchers therefore need to provide a strong
scientific justification together with assay details and sample re-
quirements. UK Biobank also welcomes proposals to recontact par-
ticipants for participation in other research studies, although these
are also carefully scrutinized and their implementation needs careful
management to avoid over-burdening participants.
Researchers are required to publish their results in an academic
journal or an open source publication site (e.g. bioRxiv) and to return
Figure 3 Plane selection for measures of distensibility and pulse
wave velocity in ascending, proximal, descending, and distal descend-
ing aorta obtained from cardiac magnetic resonance imaging (meas-
ured at the Oxford Centre for Clinical Magnetic Resonance
Research).
....................................................................................................................................................................................................................
Table 4 Overview of linkage to health-related records
Data Details Date of coverage
Death ICD-10 coded national death registry data obtained from the Health and Social Care Information Centre
(now NHS Digital) for England and Wales and the Information Services Department (ISD) for Scotland.
Contains information on source of death report, date, age and cause(s) of death
2006—ongoing
Cancer ICD-9 and -10 coded national cancer registry data obtained from HSCIC for England and Wales and the
ISD for Scotland. Contains information on source of cancer report, date and age at diagnosis, site, hist-
ology, and behaviour of the cancer.






ICD-9 and -10 coded hospital inpatient episodes obtained from the Hospital Episode Statistics provider
for England, the Patient Episode Data for Wales and the Scottish Morbidity Records for Scotland.
Contains information on admission and discharge, operations, diagnoses, maternity care, and psychi-





Primary Care Coded data from primary care records, including diagnoses, prescriptions, referrals etc. will be made
available 2017–18
Lifetime—ongoing
Other Efforts are ongoing to link to additional external datasets including hospital outpatient admissions, screen-
ing programmes, and disease-specific registries and others.
Not applicable
The authors do hereby declare that all illustrations and figures in the manuscript are entirely original and do not require reprint permission.
























































































their findings (i.e. the underlying code used to generate the findings
and any derived variables that were generated as part of the re-
search) to UK Biobank so that these can be made available to share
with other researchers.
Research interest and output
Between April 2012, when UK Biobank was opened for research use,
and April 2017, 4600 researchers had registered to use the resource,
>880 applications had been submitted and 430 projects were on-
going. Since 2013, there has been a three-fold increase in applications,
with a particular increase from international researchers (9% in 2013,
23% in 2014, 44% in 2015 and 59% in 2016), predominantly from the
USA (16% of total applications) and mainland Europe (14% of total
applications), reflecting increasing global awareness of UK Biobank as
a major resource for health-related research.
All approved research projects, including a short description of
their objectives, can be found in the following searchable database:
http://www.ukbiobank.ac.uk/approved-research/. More than 100 ap-
plications are focused on ‘cardiovascular disease’, which is, to date,
the most common health outcome of research interest in UK
Biobank. The vast majority of applications have been ‘data only’ re-
quests (>95%), although projects are now underway that have re-
quested biological samples (e.g. for exome sequencing or copy
number variant measurement) and, to a lesser extent, to re-
contacting participants to invite them to join other research studies.
The resource is still in its relatively early stages as regards research
output, but the number of publications and conference abstracts
based upon UK Biobank data are steadily increasing (http://www.
ukbiobank.ac.uk/published-papers/). By January 2017, more than 130
peer-reviewed journal articles had been published, including several
within the area of cardiovascular research. These have mainly
involved cross-sectional associations between traditional risk factors
and cardiovascular disease.27–29 However, as more incident cases ac-
crue, research will begin to take advantage of the prospective nature
of the cohort.
Genotyping data for the first 150 000 participants became available
in November 2015, and results using this data are beginning to
emerge. For example, a recently published study found that a subset
of ‘favourable adiposity’ alleles associated with higher likelihood of
adiposity were in turn associated with a lower risk of hypertension
and heart disease.30 Several genome-wide association studies have
also identified novel genetic variants linked with blood pressure
phenotypes.31,32 The genotyping data for all 500 000 participants will
be released during 2017, and a corresponding increased interest
from the research community in using the genetic data is expected.
Conclusion
Observational cohort studies have been essential in informing the
prevention and treatment of cardiovascular diseases and identifying
the role of cardiovascular risk factors in disease development.
However, previous cohorts have either been too small to investigate
less common diseases or lacked the depth of data to explore the
complex interplay between different factors and cardiovascular
disease risk. UK Biobank combines a large sample size of half a mil-
lion participants with an unprecedented amount of phenotypic and
genotypic data as well as ongoing linkage to health records. This
open-access resource provides researchers worldwide with the op-
portunity to address a wide variety of novel research questions with
the aim of improving the prevention, treatment and diagnosis of car-
diovascular disease.
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